Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan

Hiroki Ikeda, Tsunamasa Watanabe, Masanori Atsukawa, Hidenori Toyoda, Koichi Takaguchi, Makoto Nakamuta, Nobuyuki Matsumoto, Chiaki Okuse, Toshifumi Tada, Akemi Tsutsui, Naoki Yamashita, Chisa Kondo, Korenobu Hayama, Keizo Kato, Norio Itokawa, Taeang Arai, Noritomo Shimada, Toru Asano, Haruki Uojima, Chikara OgawaShigeru Mikami, Tadashi Ikegami, Shinya Fukunishi, Akira Asai, Etsuko Iio, Akihito Tsubota, Atsushi Hiraoka, Akito Nozaki, Hironao Okubo, Yoshihiko Tachi, Akio Moriya, Tsunekazu Oikawa, Yoshihiro Matsumoto, Shuichi Tsuruoka, Joji Tani, Kan Kikuchi, Katsuhiko Iwakiri, Yasuhito Tanaka, Takashi Kumada

Research output: Contribution to journalArticlepeer-review

11 Citations (Scopus)

Fingerprint

Dive into the research topics of 'Evaluation of 8-week glecaprevir/pibrentasvir treatment in direct-acting antiviral-naïve noncirrhotic HCV genotype 1 and 2infected patients in a real-world setting in Japan'. Together they form a unique fingerprint.

Medicine & Life Sciences